# ğŸ“Š Analyzing the Financial Impact of COVID-19 on Pfizer (2018â€“2024)

## ğŸ§¾ Project Description:
This project explores the dramatic shift in Pfizerâ€™s revenue structure caused by the COVID-19 pandemic. Using public financial data from trusted sources, we analyzed how the launch of Comirnaty (Pfizer's COVID-19 vaccine) and Paxlovid (antiviral treatment) affected the companyâ€™s overall revenue between 2018 and 2024.

The goal is to understand the financial boom caused by pandemic-related products and the companyâ€™s gradual return to its traditional revenue streams post-COVID.

---

## ğŸ› ï¸ Tools & Technologies Used:
- Python (Pandas, Matplotlib)
- CSV (data storage and manipulation)
- Power BI / Excel (optional dashboard layer)
- Public Sources (MacroTrends, Pfizer Annual Reports)

---

## ğŸ“ Dataset Includes:
- Annual total revenue from 2018 to 2024  
- COVID-related product revenue  
- Non-COVID product revenue  
- COVID-related revenue as a % of total revenue  

---

## ğŸ“Š Key Insights:
- **2020**: COVID revenue was minimal (~$1.7B)
- **2021**: Revenue jumped to $36.8B due to vaccine launch
- **2022**: COVID-related products made up **56%** of Pfizerâ€™s total revenue
- **2023â€“2024**: Sharp decline in COVID sales to $12.5B and then lower, making up ~16% of total revenue in 2024

---

## ğŸ“Œ Conclusion:
COVID-19 caused a massive, but temporary, transformation in Pfizerâ€™s business model. The company experienced unprecedented financial growth through pandemic products but began transitioning back to its core therapeutic areas (oncology, chronic disease, vaccines) by 2023.

---

## ğŸ“ˆ Sample Visualizations:
- Line charts showing YoY revenue changes
- Pie charts comparing COVID vs. non-COVID revenue
- Bar graphs tracking % contribution of COVID-related products over time

---

## ğŸ“‚ Project Status:
âœ… Data collected  
âœ… Analysis complete  
âœ… Visuals created  
ğŸ•— Dashboard (optional) in progress  
